Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?
- PMID: 29955496
- PMCID: PMC6007657
- DOI: 10.9740/mhc.2017.01.039
Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?
Abstract
Ayahuasca is a traditional psychoactive sacrament that's been used in Amazonian shamanic rituals for hundreds of years. Ayahuasca is notorious for its psychedelic properties produced from the combination of monoamine oxidase inhibitors (MAOIs) found in the Banisteriopsis caapi vine and N-N-dimethyltryptamine from Psychotria viridis or Diplopterys cabrerana. Recently, ritual use of ayahuasca has increased and garnered attention for its potential in treating mental illnesses, such as substance use and depressive disorders. Due to its MAOI properties, there are serious drug interactions that may be of concern among patients who participate in ayahuasca use. The objectives of this paper are to describe ayahuasca's pharmacology, potential drug interactions, and clinical data for its treatment potential in psychiatric illness.
Keywords: ayahuasca; dimethyltryptamine; harmine; monoamine oxidase; sacrament.
Conflict of interest statement
Disclosures: Benjamin J. Malcolm has no relevant conflicts of interest or financial relationships to disclose. Kelly C. Lee is a consultant for Otsuka America Pharmaceutical, Inc. Kenneth W. Tupper, PhD, is an adjunct professor, School of Population & Public Health at the University of British Columbia, and works in public health policy at the British Columbia Ministry of Health. He provided manuscript review for accuracy pertaining to anthropological, legal, and policy approaches regarding ayahuasca. He has no relevant conflicts of interest or financial relationships to disclose.
Similar articles
-
Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.Curr Neuropharmacol. 2019;17(2):108-128. doi: 10.2174/1570159X16666180125095902. Curr Neuropharmacol. 2019. PMID: 29366418 Free PMC article. Review.
-
Ayahuasca: What Healthcare Providers Need to Know.J Addict Nurs. 2021 Apr-Jun 01;32(2):167-173. doi: 10.1097/JAN.0000000000000405. J Addict Nurs. 2021. PMID: 34060770
-
Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant.Biomolecules. 2022 Nov 2;12(11):1618. doi: 10.3390/biom12111618. Biomolecules. 2022. PMID: 36358968 Free PMC article. Review.
-
The globalization of ayahuasca: harm reduction or benefit maximization?Int J Drug Policy. 2008 Aug;19(4):297-303. doi: 10.1016/j.drugpo.2006.11.001. Epub 2006 Dec 4. Int J Drug Policy. 2008. PMID: 18638702
-
Mutagenicity of Ayahuasca and Their Constituents to the Salmonella/Microsome Assay.Environ Mol Mutagen. 2019 Apr;60(3):269-276. doi: 10.1002/em.22263. Epub 2018 Nov 29. Environ Mol Mutagen. 2019. PMID: 30488498
Cited by
-
Serotonin toxicity of serotonergic psychedelics.Psychopharmacology (Berl). 2022 Jun;239(6):1881-1891. doi: 10.1007/s00213-021-05876-x. Epub 2021 Jul 12. Psychopharmacology (Berl). 2022. PMID: 34251464 Review.
-
[Ayahuasca-induced psychosis in a patient with bipolar disorder].Nervenarzt. 2019 Nov;90(11):1154-1155. doi: 10.1007/s00115-019-0728-0. Nervenarzt. 2019. PMID: 31073671 German. No abstract available.
-
Evaluation of the Cytotoxicity of Ayahuasca Beverages.Molecules. 2020 Nov 28;25(23):5594. doi: 10.3390/molecules25235594. Molecules. 2020. PMID: 33260723 Free PMC article.
-
Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico.Front Pharmacol. 2022 Jun 27;13:905753. doi: 10.3389/fphar.2022.905753. eCollection 2022. Front Pharmacol. 2022. PMID: 35833023 Free PMC article. Review.
-
5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?Psychopharmacology (Berl). 2025 Jul;242(7):1457-1479. doi: 10.1007/s00213-023-06517-1. Epub 2023 Dec 11. Psychopharmacology (Berl). 2025. PMID: 38072874 Review.
References
-
- Tupper KW, Wood E, Yensen R, Johnson MW. . Psychedelic medicine: a re-emerging therapeutic paradigm. CMAJ. 2015; 187 14: 1054- 9. DOI: 10.1503/cmaj.141124. PubMed PMID: 26350908. - DOI - PMC - PubMed
-
- Blainey MG. . Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society. J Relig Health. 2015; 54 1: 287- 302. DOI: 10.1007/s10943-014-9826-2. PubMed PMID: 24477460. - DOI - PubMed
-
- Eisner B. . Set, setting, and matrix. J Psychoactive Drugs. 1997; 29 2: 213- 6. DOI: 10.1080/02791072.1997.10400190. PubMed PMID: 9250949. - DOI - PubMed
-
- Winkelman M. . Drug tourism or spiritual healing? Ayahuasca seekers in Amazonia. J Psychoactive Drugs. 2005; 37 2: 209- 18. DOI: 10.1080/02791072.2005.10399803. PubMed PMID: 16149335. - DOI - PubMed
-
- Kavenská V, Simonová H. . Ayahuasca tourism: participants in shamanic rituals and their personality styles, motivation, benefits and risks. J Psychoactive Drugs. 2015; 47 5: 351- 9. DOI: 10.1080/02791072.2015.1094590. PubMed PMID: 26514589. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources